What are the contraindications of rhIL - 11 injection?
rhIL-11, or recombinant human interleukin-11, is a crucial cytokine that plays a significant role in the regulation of hematopoiesis, particularly in the production of platelets. rhIL-11 injection is widely used in clinical practice to prevent severe thrombocytopenia in patients undergoing myelosuppressive chemotherapy. As a reliable supplier of rhIL-11 injection, it is essential to understand its contraindications to ensure the safe and effective use of this product.
1. Hypersensitivity to rhIL-11 or Any of Its Components
The most straightforward and critical contraindication is hypersensitivity to rhIL-11 or any of the excipients in the injection. Hypersensitivity reactions can range from mild skin rashes, itching, and hives to severe anaphylactic shock, which can be life - threatening. Patients who have a history of allergic reactions to rhIL-11 or related substances should not receive this injection. Before administering rhIL-11 injection, a detailed medical history, including a history of allergies, should be obtained from the patient. In case of any suspicion of hypersensitivity, appropriate allergy testing may be required.
2. Severe Cardiac Conditions
rhIL-11 injection has been associated with an increased risk of cardiovascular adverse events. Patients with severe cardiac conditions such as congestive heart failure, uncontrolled arrhythmias, or recent myocardial infarction are at a higher risk of experiencing exacerbation of their cardiac problems when using rhIL-11. The cytokine can cause fluid retention, which may put additional strain on the heart. In patients with pre - existing cardiac insufficiency, this extra burden can lead to decompensation of heart function, resulting in worsening heart failure symptoms such as shortness of breath, edema, and fatigue. Therefore, in patients with severe cardiac disease, the potential benefits of rhIL-11 injection in preventing thrombocytopenia must be carefully weighed against the risks of cardiovascular complications.
3. Renal Impairment
Renal function is an important factor to consider when using rhIL-11 injection. Since the kidneys are responsible for the clearance of many drugs and metabolites, patients with severe renal impairment may have altered pharmacokinetics of rhIL-11. In patients with end - stage renal disease, the accumulation of rhIL-11 in the body may occur, increasing the risk of adverse effects. Additionally, fluid and electrolyte imbalance, which is common in renal impairment, can be further exacerbated by the fluid - retaining effects of rhIL-11. Close monitoring of renal function, including serum creatinine, blood urea nitrogen, and electrolyte levels, is necessary in patients with renal impairment who are considering rhIL-11 injection. Dose adjustment may be required based on the degree of renal impairment.
4. Pregnancy and Lactation
The use of rhIL-11 injection during pregnancy and lactation is a complex issue. Animal studies have shown potential adverse effects on embryo - fetal development. Although there is limited data on the use of rhIL-11 in pregnant women, the potential risks to the fetus cannot be ignored. Therefore, rhIL-11 injection should generally be avoided during pregnancy, especially in the first trimester when the fetus is most vulnerable to teratogenic effects. In cases where the use of rhIL-11 is considered necessary, a thorough discussion of the risks and benefits between the healthcare provider and the patient is required.
Regarding lactation, it is not known whether rhIL-11 is excreted in human milk. Since there is a potential risk of adverse effects on the nursing infant, breastfeeding should be discontinued during treatment with rhIL-11 injection.
5. Co - administration with Certain Drugs
There are also contraindications related to the co - administration of rhIL-11 injection with certain drugs. For example, the concomitant use of rhIL-11 with drugs that can also cause fluid retention or electrolyte imbalance may increase the risk of these adverse effects. Diuretics may be used to manage the fluid - retaining effects of rhIL-11, but their co - administration requires careful monitoring of fluid and electrolyte status.
In addition, drugs that affect the immune system may interact with rhIL-11. For instance, immunosuppressive agents may alter the response to rhIL-11, potentially reducing its effectiveness in promoting platelet production. Therefore, when considering the use of rhIL-11 injection, a comprehensive review of the patient's current medication list is necessary to identify any potential drug - drug interactions.
6. Other Considerations
Patients with a history of central nervous system disorders, such as seizures or cerebrovascular accidents, may also need special attention when using rhIL-11 injection. Although the exact mechanism is not fully understood, there have been reports of neurological adverse events associated with rhIL-11 use, including dizziness, headache, and in rare cases, seizures.
As a supplier of rhIL-11 injection, we are committed to providing high - quality products and ensuring the safety of our customers. We understand that healthcare providers need to make informed decisions based on the patient's overall condition. That's why we also offer other high - quality oncology injections, such as Romosozumab Injection - Osteoporosis, CAS: 909395 - 70 - 6, Daratumumab Injection - Multiple Myeloma (CD - 38 Mab), CAS No.: 945721 - 28 - 8, and PegFilgrastim Injection– A Long Lasting RhG - CSF, CAS No.: 208265 - 92 - 3, Bulk and Injection (PFS): 6mg in 0.6ml.
If you are a healthcare provider or a distributor interested in purchasing rhIL-11 injection or any of our other products, we encourage you to contact us for further discussion. Our team of experts is ready to provide you with detailed product information, pricing, and assistance in the procurement process.
References
- Basser RL, DiPersio JF, Nademanee A, et al. Randomized phase III trial of recombinant human interleukin 11 in cancer patients with severe thrombocytopenia due to chemotherapy. J Clin Oncol. 1996;14(11):2986 - 2994.
- Vadhan - Raj S, Amato RJ, Beck JT, et al. Phase III randomized, double - blind, placebo - controlled trial of recombinant human interleukin 11 in patients with solid tumors receiving myelosuppressive chemotherapy. J Clin Oncol. 1997;15(1):336 - 343.
- Wadhwa M, Mehta K, Newland AC. Interleukin - 11: biology and use in clinical practice. Br J Haematol. 1996;94(4):720 - 728.